≥ 100mg/dL60y.o.q1ymammogramtobaccouse50y.o.40-70 y.o.,ASCVD ≥10%, lowbleeding riskpneumococcalq15yTyrer-Cuzickmodel≥ 126mg/dLGailmodelovariancanceraspirinHepatitisB≥20%hormonetherapy≤q2ydementiabreastcancerq3y≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsinsufficientevidenceforscreeningdiabetesq1-2ymammogrambased on lifeexpectancy /health status40-59 y.o.,ASCVD ≥10%, lowbleeding risk≥ 140mg/dL40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsq5ywomenage 55-64 y.o.raloxifene75y.o.HepatitisCstatin40y.o.cervicalcancerhypertension2 doses,2-6monthsapartTimedup andgo testherpeszoster< 60y.o.HIVtamoxifendepressionlungcancermultidoseinitial series,then 1 doseat 2-6monthsq1yoverweight/ obesityPREVENTequationcolorectalcancer52y.o.≥5.7%40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥6.5%dyslipidemia1 dose; 2doses (2-6monthsapart) ifimmunocomp65y.o.FractureRiskAssessmentToolanxietyq2yaromataseinhibitors40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorcardiovasculardiseasecommunity-dwelling,postmenopausalwomen≥ 200mg/dL3%≥ 100mg/dL60y.o.q1ymammogramtobaccouse50y.o.40-70 y.o.,ASCVD ≥10%, lowbleeding riskpneumococcalq15yTyrer-Cuzickmodel≥ 126mg/dLGailmodelovariancanceraspirinHepatitisB≥20%hormonetherapy≤q2ydementiabreastcancerq3y≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsinsufficientevidenceforscreeningdiabetesq1-2ymammogrambased on lifeexpectancy /health status40-59 y.o.,ASCVD ≥10%, lowbleeding risk≥ 140mg/dL40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsq5ywomenage 55-64 y.o.raloxifene75y.o.HepatitisCstatin40y.o.cervicalcancerhypertension2 doses,2-6monthsapartTimedup andgo testherpeszoster< 60y.o.HIVtamoxifendepressionlungcancermultidoseinitial series,then 1 doseat 2-6monthsq1yoverweight/ obesityPREVENTequationcolorectalcancer52y.o.≥5.7%40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥6.5%dyslipidemia1 dose; 2doses (2-6monthsapart) ifimmunocomp65y.o.FractureRiskAssessmentToolanxietyq2yaromataseinhibitors40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorcardiovasculardiseasecommunity-dwelling,postmenopausalwomen≥ 200mg/dL3%

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. ≥ 100 mg/dL
  2. 60 y.o.
  3. q1y mammogram
  4. tobacco use
  5. 50 y.o.
  6. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  7. pneumococcal
  8. q15y
  9. Tyrer-Cuzick model
  10. ≥ 126 mg/dL
  11. Gail model
  12. ovarian cancer
  13. aspirin
  14. Hepatitis B
  15. ≥20%
  16. hormone therapy
  17. ≤ q2y
  18. dementia
  19. breast cancer
  20. q3y
  21. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  22. insufficient evidence for screening
  23. diabetes
  24. q1-2y mammogram based on life expectancy / health status
  25. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  26. ≥ 140 mg/dL
  27. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  28. q5y
  29. women age 55-64 y.o.
  30. raloxifene
  31. 75 y.o.
  32. Hepatitis C
  33. statin
  34. 40 y.o.
  35. cervical cancer
  36. hypertension
  37. 2 doses, 2-6 months apart
  38. Timed up and go test
  39. herpes zoster
  40. < 60 y.o.
  41. HIV
  42. tamoxifen
  43. depression
  44. lung cancer
  45. multidose initial series, then 1 dose at 2-6 months
  46. q1y
  47. overweight / obesity
  48. PREVENT equation
  49. colorectal cancer
  50. 52 y.o.
  51. ≥ 5.7%
  52. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  53. ≥ 6.5%
  54. dyslipidemia
  55. 1 dose; 2 doses (2-6 months apart) if immunocomp
  56. 65 y.o.
  57. Fracture Risk Assessment Tool
  58. anxiety
  59. q2y
  60. aromatase inhibitors
  61. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  62. cardiovascular disease
  63. community-dwelling, postmenopausal women
  64. ≥ 200 mg/dL
  65. 3%